Introduction
The International Diabetes Federation has recently estimated that-by the year 2040-almost 500 million people will be overweight and insulin resistant while 642 million will be affected by Type 2 diabetes (T2D). 1 Obesity and T2D have many deleterious effects on the heart, including changes in substrate utilization, tissue metabolism, oxidative stress, and inflammation that are believed to promote cardiac dysfunction, and eventually heart failure (HF). [2] [3] [4] A growing body of evidence indicates that patients with glucometabolic perturbations are at risk of developing a metabolic cardiomyopathy (MC) phenotype, which is unrelated to the presence of coronary artery disease, hypertension, and other comorbidities. 5, 6 In these patients, MC mainly results from intracellular accumulation of lipotoxic by-products leading to myocyte apoptosis and contractile dysfunction. 7 Over 80% of patients affected by HF are either obese or diabetic. 8, 9 Notably, HF represents one of the leading cause of mortality in these patients. 8, 9 Although MC prevalence is expected to rise considerably over the next decades, the underlying mechanisms remain poorly understood, and breakthrough therapies have yet to be developed in this setting. 5 The accumulation of triglycerides (TG) in the heart, caused by a mismatch between uptake and oxidation of fatty acids, is emerging as a powerful determinant of cardiac damage mainly via accumulation of free radicals and subsequent activation of apoptosis. 7 Myocardial TG content is increased in T2D patients, and associates with impaired left ventricular (LV) diastolic function, regardless of age, body mass index (BMI), heart rate, visceral fat, and blood pressure. 10, 11 Of note, a consistent proportion of patients with non-ischaemic HF display intramyocardial TG overload and changes in gene expression which are associated with contractile dysfunction. 12 The Activator Protein 1 (AP-1) complex has emerged as a key modulator of cellular growth and metabolism. 13 The AP-1 dimer is composed by three different Jun proteins (c-Jun, JunB, and JunD) and four different Fos proteins (c-Fos, FosB, Fra-1, and Fra-2). These members assemble to form AP-1 transcription factors with activities that are strongly influenced by their specific components and their cellular environment. 14 The AP-1 member JunD has shown to regulate insulin signalling and hepatic TG metabolism. 15, 16 Whether JunD participates in obesity-related MC is unknown. In neonatal rat ventricular myocytes, gain-and loss-of-function mutant mice and myocardial biopsies from obese and non-obese patients, we show that the AP-1 transcription factor JunD regulates PPARc signalling, thus leading to myocardial TG accumulation, lipotoxic damage, and LV dysfunction. Our findings may set the basis for the design of new approaches to prevent MC in obesity.
Methods
A detailed description of JunD knockout mice (JunD À/À ), cardiac-specific
JunD overexpressing mice (a-MHC-JunD Tg ), in vitro experiments in neonatal rat myocytes, experiments in human heart samples, transcriptomic and lipidomic analyses, and bioinformatics and statistical methods is reported in Supplementary material online. All primers used for real-time PCR are shown in Supplementary material online, 
Statistical analysis
Comparisons of continuous variables were performed using unpaired two-sample t-test and Mann-Whitney U test, as appropriate. Categorical variables were compared using the v 2 test. Multiple comparisons were performed by one-way analysis of variance, followed by Bonferroni correction. Adjusted P values were calculated by multiplying raw P values by g, where g indicates the number of comparisons. Between variable correlations were assessed by Spearman's test. A multiple t-test using the Benjamini-Hochberg false discovery rate procedure was employed for the analysis of gene expression data (real-time PCR array). Probability values <0.05 were considered statistically significant. All analyses were performed with GraphPad Prism Software (version 7.03).
Results
JunD is required for the development of obesity-induced cardiomyopathy Diet-induced obesity was employed to investigate the role of the AP-1 transcription factor JunD in MC. In line with other reports, 17 body weight almost doubled, and blood glucose levels increased by 1.5-fold after feeding 60 kcal% high-fat diet (HFD) for 20 weeks (Supplementary material online, Figure 1A and B). Together with increased expression, JunD transcriptional activity was significantly enhanced in nuclear extracts from obese as compared with control hearts ( Figure 1C) . To understand the contribution of JunD in obesityrelated MC, we studied CD-fed and HFD-fed mice, in the presence or in the absence of JunD genetic deletion (Supplementary material online, Figure S1 ). Control diet-fed WT and JunD À/À mice were similar for anthropometric parameters and lipid fractions, whereas HFDfed JunD À/À showed decreased body weight and heart weight as compared with HFD-fed WT mice (Supplementary material online, Table S2 ). Transthoracic echocardiography was employed to assess cardiac function in the four experimental groups. When compared with CD-fed controls, HFD-fed mice showed similar diastolic and systolic LV diameters, whereas LV mass was increased in the latter group ( Figure 1D-F) . Ejection fraction (EF) and fractional shortening (FS)-both indices of systolic LV function-were impaired in obese as compared with lean animals ( Figure 1G and H). Diastolic function-assessed by both pulse wave Doppler and tissue Doppler imaging (TDI)-was also affected in obese mice, as shown by decreased E/A ratio and prolongation of isovolumic relaxation time ( Figure 1I and J, Supplementary material online, Table S3 ). Along the same line, LV myocardial performance index-a wellestablished index of systo-diastolic performance-was impaired in obese as compared with control mice ( Figure 1K) . Interestingly, HFDfed JunD À/À mice displayed reduced LV mass and were protected against LV dysfunction, thus suggesting a protective role of JunD deletion in obesity-induced cardiomyopathy ( Figure 1F -K, Supplementary material online, Table S3 ).
JunD regulates PPARc signalling in the obese heart
Given the pivotal role of peroxisome proliferator-activated receptor alpha (PPARa) and gamma (PPARc) in the pathogenesis of MC, 18, 19 their expression was investigated in CD-fed and HFD-fed WT and JunD À/À mice. Myocardial gene and protein expression of both PPARa and PPARc were increased in WT obese as compared with lean mice, while they were almost blunted in HFD-fed JunD À/À animals ( Figure 2A-D) . Next, we asked whether JunD directly regulates the transcription of PPARa and PPARc. Chromatin immunoprecipitation (ChIP) assay showed that JunD binds PPARc (region 100/-199) but not PPARa promoter in the heart of obese mice ( Figure 2E) . A custom real-time PCR array revealed a profound dysregulation of PPAR-dependent genes implicated in fatty acid synthesis (i.e. fatty acid synthase, Fas), uptake [i.e. Cd36, fatty acid binding protein 3 (Fabp3), and 4 (Fabp4)], hydrolysis (i.e. lipoprotein lipase, Lpl), and storage (i.e. perilipin 5, Plin5) in obese as compared to control hearts ( Figure 2F-H) . Notably, such maladaptive changes were not observed in the heart of HFD-fed JunD À/À mice. Figure 2G and H shows significantly down-and up-regulated PPAR-dependent genes across the four experimental groups, respectively. The full list of PPARdependent genes is provided in Supplementary material online, Table S4 .
JunD À/À mice display reduced intra-myocardial triglyceride accumulation
Based on transcriptomics data, JunD likely modulates genes involved in myocardial TG metabolism. Hence, we investigated intramyocardial TG content in CD-fed and HFD-fed WT and JunD À/À mice. Total TG levels were increased in heart specimens from obese as compared with control mice ( Figure 3A) . In contrast, myocardial TG content was not significantly affected in obese mice lacking JunD ( Figure 3A) . The latter finding was confirmed by mass spectrometry (MS)-based quantification of cardiac TG species across the different experimental groups ( Figure 3B) .
Intracellular lipid accumulation leads to unoxidized fatty acids and de novo synthesis of ceramides, 20 a class of sphingolipids involved in oxidative stress and apoptosis. 7 Hence, we performed MS-based ceramide profiling in heart samples from CD-fed to HFD-fed WT and JunD À/À mice. We found an increase of [Cer(d18:1/16:0)] and [Cer(d18:1/24:1)] in the heart of obese as compared with lean mice, whereas both ceramides were reduced in HFD-fed JunD À/À as compared with WT animals ( Figure 3C ). In line with these findings, 3-nitrotyrosine (3-NT) as well as DNA and lipid peroxidation were increased in obese WT but not in JunD À/À hearts ( Figure 3D -F). Apoptosis, assessed by activation of Caspase-3, was also significantly reduced in hearts from obese JunD À/À mice ( Figure 3G and H).
Targeting JunD blunts PPARc signalling in neonatal rat ventricular myocytes
To further prove the mechanistic link between JunD and PPARc, we performed in vitro experiments in neonatal rat ventricular myocytes (NRVMs) exposed to high concentrations of palmitic acid (PA), a condition mimicking obesity and insulin resistance. Concentrationeffects experiments showed that 48-h treatment with PA at the dose of 200 mM led to JunD up-regulation in NRVMs ( Figure 4A , Supplementary material online, Figure S2 ). Increased JunD levels in PA-treated NRVMs were associated with PPARc up-regulation ( Figure 4B ). Gene silencing of JunD by siRNA was sufficient to abolish PPARc expression in NRVMs exposed to PA ( Figure 4B) . Furthermore, PPARc-dependent genes involved in TG synthesis, uptake, hydrolysis, and storage, such as Fas, Cd36, Lpl, and Plin5, were blunted in JunD-depleted NRVMs ( Figure 4C) . Consistently, gene silencing of PPARc-prevented lipid uptake and lipotoxic damage in PA-treated NRVM (Supplementary material online, Figure S3 ). miR-206, and miR-494-3p were selected based on (i) site-type, (ii) context score, (iii) context score percentile, (iv) weighted context score, (v) conserved branch, and (vi) the probability of conserved targeting ( Figure 4D) . The expression of JunD-targeting miRNAs was assessed in the heart of HFD-fed vs. CD-fed mice. We found that miR-494-3p was down-regulated in obese as compared to nonobese hearts, whereas no significant differences were observed for miR-206 and miR-375 ( Figure 4E) . RISC(ago2)-immunoprecipitation 
was employed to demonstrate whether miR-494-3p affected the interaction of JunD mRNA with Argonaute 2 (Ago2), a major component of the RISC complex. The association of JunD mRNA with Ago2 was assayed by real-time PCR of JunD mRNA in Ago2 immunoprecipitates (IP). We found that JunD mRNA in Ago2 IP samples was enriched by miR-494-3p, thus validating that miR-494-3p facilitates endogenous JunD mRNA association with RISC ( Figure 4F) . To confirm that miR-494-3p directly represses JunD expression, a luciferase gene reporter assay was performed in NRVMs. To assess the effects of miR-494-3p on JunD 3'-UTR, luciferase reporter plasmids containing full length JunD 3'-UTR (WT) or 3'-UTRs with a mutation in miR-494-3p 'seed'-binding site (JunD 3 0 -UTRmut) were constructed. In the luciferase reporter assay, co-transfection of JunD 3 0 -UTR with miR-494-3p caused a significant reduction of 3'-UTR JunD luciferase activity as compared to allStar negative control. In contrast, cells transfected with JunD 3 0 -UTRmut construct were not sensitive to miR-494-3p treatment ( Figure 4G) . We then overexpressed miR-494-3p in PA-treated NRVMs to investigate its putative role in preventing lipotoxic damage through modulation of JunD levels. Consistent with our observations in the mouse, PA treatment significantly reduced miR-494-3p expression in cultured NRVMs (Supplementary material online, Figure S4 ). 
Conversely, miR-494-3p overexpression attenuated PA-induced JunD up-regulation ( Figure 4H) . Overexpression of miR-494-3p also reduced myocardial TG uptake, oxidative stress and apoptosis, thus confirming its role in the regulation of JunD/PPARc axis ( Figure 4I-K) .
Cardiac-specific JunD overexpression mimics obesity-induced metabolic cardiomyopathy
To determine whether JunD-dependent regulation of TG metabolism is cardiomyocyte specific, we used transgenic mice overexpressing JunD (JunD Tg ) via the cardiac a-myosin heavy chain (a-MHC) promoter. 22 WT littermates were used as a control group. Western blot analysis and immunohistochemistry confirmed overexpression of JunD in the heart (Supplementary material online, Figure S5 ). Cardiac-specific overexpression of JunD was associated with an impairment of LV systolic function, as assessed by EF and FS ( Figure 5A and B, Supplementary material online, Table S5 ). Indices of diastolic function and LV performance were also impaired in JunD Tg as compared to WT littermates ( Figure 5C-E) . Of interest, PPARa and PPARc were strongly up-regulated in the heart of JunD Tg mice as compared to control animals ( Figure 5F -I), suggesting that cardiacspecific JunD activation mimics obesity-induced MC. Chromatin immunoprecipitation assay confirmed that JunD binds PPARc (region 100/-199) but not PPARa promoter in JunD Tg hearts ( Figure 5J) .
Moreover, PPARc-dependent genes Fas, Cd36, Lpl, and Plin5 were up-regulated in JunD
Tg as compared to WT mice ( Figure 5K) . Similarly, TG content in heart homogenates was enhanced in JunD Tg as compared to control hearts ( Figure 5L ) and was associated with high 3-NT levels and activation of Caspase-3 ( Figure 5M and N) . These findings were confirmed in cultured NRVMs, where JunD overexpression led to up-regulation of PPARc as well as PPARc-dependent genes implicated in TG accumulation and lipotoxic damage (Supplementary material online, Figure S6 ). 
JunD/PPARc signalling in cardiac specimens from obese patients
In order to translate our experimental findings to human disease, JunD/PPARc signalling was investigated in right atrial specimens collected from obese patients and age-matched non-obese individuals undergoing cardiopulmonary bypass for coronary artery bypass grafting and surgical valve replacement. Obese patients had higher BMI, LV diameters, LV mass, and impaired cardiac function as compared to non-obese subjects (Supplementary material online, Table S6 ). In line with our experimental observations, JunD gene and protein expression were higher in the myocardium of obese patients as compared to lean controls ( Figure 6A) . In obese patients, increased cardiac JunD levels were associated with down-regulation of miR-494-3p ( Figure 6B) . PPARc, PPARa and PPAR-dependent genes Fas, Cd36, Lpl, and Plin5 were also dysregulated in obese vs. non-obese hearts ( Figure 6C and D) . Consistently, myocardial TG content was higher in obese vs. non-obese patients ( Figure 6E) . Cardiac gene expression of JunD positively correlated with BMI, myocardial TG content, LV mass, and TDI-derived E/Em ratio, a reliable indicator of LV diastolic dysfunction (Figure 7A-D) . Interestingly, JunD also correlated with the expression of PPARa, PPARc, and PPAR-dependent genes involved in myocardial TG accumulation (Supplementary material online, Figure S7 ). Negative correlations were found with indices of LV systolic function, such as EF and FS as well as with miR-494-3p ( Figure 7E-G) .
Discussion
The present study demonstrates that the AP-1 transcription factor JunD participates to MC both in experimental and human obesity (Take home figure) . Several lines of evidence support our conclusions: (i) JunD is up-regulated in the heart of obese mice, and contributes to transcriptional modulation of PPARc and PPARc-dependent genes implicated in TG uptake, storage, and hydrolysis; (ii) obese mice with genetic deletion of JunD do not show alterations of PPARc signalling and are protected against myocardial TG accumulation, lipotoxic damage, and LV systo-diastolic dysfunction; (iii) cardiac-specific overexpression of JunD in non-obese mice mimics molecular and functional features of MC; (iv) miR-494-3p directly targets JunD in the obese heart, and its overexpression prevents JunD/PPARc activation Obesity currently affects 400 million people worldwide and it is emerging as a potent risk factor for the development of LV dysfunction, independently of hypertension, coronary artery disease, or valvular heart disease. 23, 24 Prevalence of obesity continues to escalate and will have an important impact on the development of HF in the decades to come. 25 Of note, little diagnostic and therapeutic tools are available to fight obesity-related MC and its complications. Altogether these factors call for understanding the mechanistic basis underlying MC in obese patients. Here, we show that the AP-1 member JunD is an upstream regulator of PPARc in the obese heart, leading to the transcription of PPAR-dependent genes (i.e. Cd36, Fabp3, Fabp4, Fas, Plin5, Lpl) involved in lipid uptake, hydrolysis, and storage. CD36 and FABP3/4 are pivotal mediators of myocardial lipid uptake, whereas LpL and Plin5 foster lipid droplet formation and storage. 7 Along the same line, FAS amplifies lipid accumulation by promoting de novo synthesis of fatty acids in myocardial cells. 26 We also observed that JunD deletion prevents obesity-induced accumulation of pro-apoptotic ceramides, namely Cer[(d18:1/16:0)] and Cer[(d18:1/24:1)]. The relevance of this finding is supported by the notion that both these ceramides predict HF and mortality in patients with cardiovascular disease. 27 Although JunD activation was associated with the induction of both PPARa and PPARc, ChIP assay showed that the former is not directly regulated by JunD. Increased
PPARa expression in our setting may be interpreted as a compensatory but futile mechanism in response to increased TG content and up-regulation of PPARa-activating genes, namely FAS. 7 The impact of JunD in the setting of obesity is supported by its ability to foster macrophage activity, cytokine secretion, and steatohepatitis, 16, 28 key hallmarks of cardiometabolic disturbances. Consistent with our observations, JunD À/À mice showed reduced hypertrophic response and decreased expression of brain natriuretic peptide after transverse aortic constriction (TAC), whereas cardiomyocytespecific overexpression of JunD was associated with LV dilation and dysfunction. 22 In contrast, other studies reported that JunD attenuates both phenylephrine and TAC-mediated cardiomyocyte hypertrophy, 29, 30 suggesting a dual role in hypertrophic response upon different stimuli and experimental conditions. Previous work showed that mice with JunD deletion have enhanced insulin signalling and reduced weight gain when fed a HFD. 15, 16 Similarly, in the present study we observed that obese JunD À/À mice had lower body weight as compared to obese WT animals. To rule out possible systemic effects of JunD deletion in obesity, we studied mice with cardiacspecific overexpression of JunD. The latter experimental model allowed us to conclude that cardiac JunD activation is sufficient to induce maladaptive metabolic remodelling and lipotoxic damage, thus phenocopying obesity-related MC. Given the emerging link among environmental factors, obesity, and non-coding RNAs, 31 we explored the role of miRNAs as modulators of JunD levels. Among JunD-targeting miRNAs, we found that miR-494-3p was down-regulated in the heart of obese mice as compared to lean controls. Interestingly, overexpression of miR-494-3p blunted JunD levels and lipotoxic damage in NRVMs exposed to PA, a wellestablished model mimicking the effects of obesity. 32 These findings are in line with previous work showing that cardiac-specific overexpression of miR-494-3p protects against ischaemia-reperfusion injury and myocardial apoptosis. 33 As a clinical translation, we also demonstrate that JunD signalling was profoundly altered in the myocardium of obese patients and was associated with up-regulation of lipid droplet-associated genes and TG accumulation. Interestingly, JunD gene expression correlated with echocardiographic indices of systo-diastolic function, such as EF, FS, and TDI-derived E/Em ratio, a sensitive indicator of diastolic dysfunction and cardiovascular events. 34 Our manuscript has some limitations. First, obesity-driven JunD up-regulation was not determined in an unbiased way. Our approach does not allow to appreciate the differential contribution of other transcription factors to the observed phenotype. However, transcriptomic analysis in T2D rat hearts has unveiled JunD as one of the top-ranking up-regulated genes, suggesting its pivotal role in comparison with other transcription factors. 35 Second, a constitutive JunD 
knockout model was employed in our study, hence we cannot exclude the possibility that the absence of JunD in tissues other than the myocardium could have played a role in our setting. Nevertheless, experiments in mice with cardiac-specific overexpression of JunD and cultured myocytes suggest that cardiac JunD activation is sufficient to induce maladaptive metabolic remodelling and lipotoxic damage. Third, we did not investigate whether JunD impacts on myocardial insulin resistance, a key feature of obesity cardiomyopathy. Our findings are in line with previous work showing that JunD negatively regulates insulin signalling. 15 Moreover, CD36 has been regarded as an insulin-resistance gene causing defective fatty acid and glucose metabolism. 36 Here, we show that JunD leads to a PPARcdependent up-regulation of CD36, and this might contribute to dampen myocardial insulin signalling by shifting the metabolic substrate.
In the present study, we have employed an advanced microultrasound imaging system which allows to reduce speckle noise and artefacts while preserving and enhancing critical information. However, the echocardiographic assessment of cardiac function in small animals presents some limitations mainly due to elevated heart rate. 37 In conclusion, our translational study unveils a new molecular mechanism contributing to obesity-related MC. These findings improve our understanding of the pathophysiology of MC, and may set the stage for novel strategies to prevent or treat lipotoxic LV dysfunction in patients with obesity.
